PET imaging of tumour hypoxia

Anwar Padhani

Paul Strickland Scanner Centre, Mount Vernon Hospital, Rickmansworth Road, Northwood, Middlesex, HA6 2RN, UK

Corresponding address: Dr Anwar Padhani FRCP FRCR, Paul Strickland Scanner Centre, Mount Vernon Hospital, Rickmansworth Road, Northwood, Middlesex, HA6 2RN, UK
E-mail: anwar.padhani@paulstrickland-scannercentre.org.uk

Abstract
Tumour hypoxia represents a significant challenge to the curability of human tumours leading to treatment resistance and enhanced tumour progression. Tumour hypoxia can be detected by non-invasive and invasive techniques but the inter-relationships between these remains largely undefined. $[^{18}\text{F}]$Fluoromisonidazole-3-fluoro-1-(2′-nitro-1′-imidazolyl)-2-propanol ($[^{18}\text{F}]$MISO) and Cu-diacetyl-bis($N^4$-methylthiosemicarbazone (Cu-ATSM)-positron emission tomography (PET), and blood oxygen level-dependent (BOLD)-magnetic resonance imaging (MRI) are the lead contenders for human application based on their non-invasive nature, ease of use and robustness, measurement of hypoxia status, validity, ability to demonstrate heterogeneity and general availability; PET techniques are the primary focus of this review.

Keywords: Hypoxia; radiotherapy; cancer; F-MISO-PET; Cu-ATSM-PET; tumour resistance.

Introduction
The fact that hypoxia increases tumour resistance to the effects of radiotherapy has been known for over 70 years. Forty-five years ago, Tomlinson and Gray showed that hypoxia exists in human tumours and that necrosis occurs about 100 µm from the nearest blood vessel which is also the diffusion distance of soluble oxygen$^{[1]}$. Decades of research in radiation therapy have focused on attempts to circumvent hypoxia mediated radio-resistance with moderate success. Over the last decade, it has become known that hypoxia changes the pattern of gene expression that alters the malignant potential of tumours leading to more aggressive survival traits, as a result of which cancer cells become difficult to treat by radiation and chemotherapy$^{[2]}$.

Tumour hypoxia overview
For the majority of solid tumours hypoxia develops because of the inability of the vascular system to supply the growing tumour mass with adequate amounts of oxygen. Tumour growth beyond 2 mm requires tumour neovascularisation to both supply oxygen and nutrients. The major factors in the development of tumour cell hypoxia are the known abnormalities in structure and functioning of tumour microvessels$^{[3]}$, the increased diffusion distances between blood vessels (many of which may not even carry oxygenated red blood cells), the expanding tumour cell mass with increased metabolic needs and the reduced oxygen carrying capacity of blood due to disease- or treatment-related anaemia. Thus, there are three distinct types of tumour hypoxia$^{[4]}$:

1. Perfusion related (acute) hypoxia which results from inadequate blood flow in tumours; it is generally the consequence of recognised structural and functional abnormalities of the tumour neovascularature. Such acute hypoxia is often transient, caused by temporary occlusions and temporary rises in interstitial pressure. Such hypoxia affects tumour cells right up to the vessel wall.

2. Diffusion related (chronic) hypoxia is caused by increased oxygen diffusion distances due to tumour expansion and affects tumour cells greater than 70–100 µm from the nearest capillary, depending on
where tumour cells lie in relation to the arterial or venous end of capillaries.

(3) Anaemic hypoxia, which is related to the reduced O₂-carrying capacity of the blood.

As noted above, the presence of tumour hypoxia appears to impair the effectiveness of radiotherapy and radiosensitivity is progressively limited as tumour pO₂ levels fall. Hypoxia-induced radioresistance is multifactorial with the presence of oxygen mediating DNA damage through the formation of oxygen free radicals which occurs after the interaction of radiation with intracellular water. The ratio of doses administered under well-oxygenated to hypoxic conditions needed to achieve the same biological effect (i.e. cell kill) is called the oxygen enhancement ratio (OER). For sparsely ionising radiations such as X- and gamma rays, the OER at therapeutic doses is between 2.5 and 3.5[5]. That is, well oxygenated cells are about three times more sensitive to X- and gamma radiation than the same cells when they are hypoxic. Half maximal sensitivity to X- and gamma rays occurs at oxygen tensions of approximately 2–5 mmHg; above pO₂ values of approximately 10–15 mmHg near maximal oxygen effects are seen. However, it should be recognised that sensitivity of cells to radiation is dependent on the phase of the cell cycle, with cells in the G₁ phase having a lower OER (i.e. more radiosensitive) than cells in S-phase. As noted above, the oxygen effect is not the only mechanism for radioresistance in hypoxic tumour cells. Evidence is accumulating that the hypoxia-mediated proteomic and genomic changes may also contribute to radioresistance by increasing the levels of heat shock proteins (HSPs) (HSPs are induced in response to environmental stresses like heat, cold and oxygen deprivation[6]) or by increasing the number of tumour cells that can resist apoptosis by mutating p53 (the slowing of cell division is dependent on a protein brake known as p53; the disruption of the functioning of this protein is associated with approximately 50–55% of human cancers).

The presence of hypoxia within human tumours before starting treatment has been observed in squamous cell carcinomas, gliomas, adenocarcinomas (breast and pancreas) and in sarcomas. Oxygen probes, that is, electrodes implanted directly into tissues have shown that the normal cervix pO₂ is a median of 42 mmHg compared to a median of 10 mmHg in squamous carcinomas[7–9]. Furthermore, in cervix cancer, for example, the oxygenation status is independent of size, stage, histopathological type, grade of malignancy, and heterogeneity within and between the same tumour types. Hypoxia contributes to poor prognosis; pO₂ < 10 mmHg results in poor local tumour control, disease-free survival and overall survival in squamous carcinomas of the head and neck and of cervix cancers[10,11].

There is debate about whether there is a critical intratumoural pO₂ below which detrimental changes begin to occur that is common across cell types. This occurs because experiments performed in cell cultures may not be applicable to in vivo environments and some of the literature variation can be attributed to the tumour cell type chosen for experiments and the demands of host tissues. With these caveats in mind, the critical pO₂ tensions below which cellular functions progressively cease or anticancer treatments are impaired are approximately as follows[12]: effectiveness of immunotherapy becomes impaired (30–35 mmHg); photodynamic therapy (15–35 mmHg); cell death on exposure to radiation (25–30 mmHg); binding of hypoxia immunohistochemical markers (10–20 mmHg); proteome changes (1–15 mmHg) and genome changes (0.2–1 mmHg). The differences in these numbers are smaller than the similarities so that, from a practical perspective, for solid tissue tumors in vivo, a value of between 5 and 15 mmHg is a good number to remember because of its impact on therapy.

Clinical imaging of hypoxia

There are a number of ways in which tissue oxygenation status can be assessed in vivo (both invasive and non-invasive) or in vitro using material from biopsy. Non-imaging methods of assessing for the presence of hypoxia in tissues include histological appearance, immunohistochemical staining for intrinsic markers of hypoxia (e.g. carbonic anhydrase IX (CA-IX) and hypoxia inducible factor-1 (HIF-1)) and for the binding of externally administered nitroimidazoles[13]. From an imaging perspective, an ideal test would: (1) distinguish normoxia/hypoxia/anoxia/necrosis; (2) distinguish between perfusion-related (acute) and diffusion-related (chronic) hypoxia if possible; (3) reflect cellular in preference to vascular pO₂; (4) be applicable to any tumour site with complete loco-regional evaluation; (5) be simple to perform, non-toxic and allow repeated measurements, and (6) be sensitive at pO₂ levels relevant to tumour therapy. Therefore, the challenge for hypoxia imaging is to measure low levels of tissue pO₂ on a spatial scale smaller than the similarities so that, from a practical perspective, an ideal test would: (1) distinguish normoxia/hypoxia/anoxia/necrosis; (2) distinguish between perfusion-related (acute) and diffusion-related (chronic) hypoxia if possible; (3) reflect cellular in preference to vascular pO₂; (4) be applicable to any tumour site with complete loco-regional evaluation; (5) be simple to perform, non-toxic and allow repeated measurements, and (6) be sensitive at pO₂ levels relevant to tumour therapy. Therefore, the challenge for hypoxia imaging is to measure low levels of tissue pO₂ on a spatial scale similar to the O₂ diffusion distance (70–100 μm), a much smaller dimension than can be achieved with human imaging techniques. [¹⁸F]Fluoromisonidazole-3-fluoro-1-(2′-nitro-1′-imidazolyl)-2-propanol ([¹⁸F]MISO) and [⁶⁰/⁶⁴Cu]diacetyl-bis(N⁴-methylthiosemicarbazone (Cu-ATSM)-positron emission tomography (PET), the leading imaging contenders, are compared with other techniques in Table 1 and discussed in greater detail below.

[¹⁸F]MISO

[¹⁸F]MISO is the prototype hypoxia imaging agent. Uptake is homogeneous in most normal tissues, reflecting its high partition coefficient (near unity), and delivery...
to tumours is not limited by perfusion\[14\]. The initial distribution of \[^{18}\text{F}]\text{MISO}\ is flow dependent, as with any freely diffusible tracer, but local oxygen tension is the major determinant of its retention above normal background in tissues after 2 h. \[^{18}\text{F}]\text{MISO}\ accumulates in tissues by binding to intracellular macromolecules when \(p\text{O}_2 < 10 \text{ mmHg}\). Retention within tissues is dependent on nitroreductase activity (i.e. on reduction status of a NO\(_2\) group on the imidazole ring) and accumulation in hypoxic tissues over a range of blood flows has been noted, including within the intestinal lumen where it is retained in anaerobes.

Hypoxia can be imaged with \[^{18}\text{F}]\text{MISO PET}\ in a procedure that is well tolerated by the patients. Imaging requires 20–30 min and starts anywhere from 75 to 150 min after injection, making it similar to the bone scan with which most cancer patients are familiar. Useful and well-validated images can be achieved with a modest dose of radiation, typically 250 MBq. No arterial sampling or metabolite analysis is required and synthesis is achieved through relatively simple modifications of nucleophilic displacement/deprotection synthesis boxes such as are used for fluorodeoxyglucose (\[^{18}\text{F}]\text{FDG}\). In the United States, F-MISO has Investigational New Drug (IND) authorization from the Food and Drug Administration (FDA) as an investigational product for use in humans. Unlike Eppendorf \(p\text{O}_2\) histogramry, \[^{18}\text{F}]\text{MISO}\ is only sensitive to the presence of hypoxia in viable cells; \[^{18}\text{F}]\text{MISO}\ is not retained in necrosis because the electron transport chain that reduces the nitroimidazole to a bioreductive alkylating agent is no longer active. Limitations of \[^{18}\text{F}]\text{MISO PET}\ include the modest signal-to-noise ratio of raw \[^{18}\text{F}]\text{MISO PET}\ images but if a venous blood sample is acquired during the mid-course of the imaging procedure and used to calculate a tumour/blood (T/B) ratio image, then normoxic uptake (T/B < 1) can be electronically subtracted to increase image contrast. Several studies in a range of hypoxic tumours, stroke and hypoxic myocardium\[15\] have shown that a T/B of >1.2 reliably identifies the presence of hypoxia. The presence of high normal liver uptake impairs complete assessment of liver lesions and urinary excretion interferes with imaging near the bladder.

\[^{18}\text{F}]\text{MISO PET}\ is able to monitor the changing hypoxia status of lung tumours during radiotherapy\[16\]. Studies in sarcoma\[17\] and head and neck cancer\[18–20\] have demonstrated a correlation of \[^{18}\text{F}]\text{MISO PET}\ uptake with poor outcome to radiation and chemotherapy.

\section*{Cu-ATSM}

Cu-ATSM holds exceptional promise as an agent for delineating the extent of hypoxia within tumours with PET. Numerous pre-clinical studies have evaluated and validated its use for imaging of hypoxia in tumours and other tissues\[21–28\]. The mechanism of retention of the reagent in hypoxic tissues is largely attributed to the low oxygen tensions and the subsequent altered redox environment of hypoxic tumours (increased NADH levels). Clinical studies, well tolerated by patients, involved \[^{60}\text{Cu}]\text{ATSM}\ imaging sessions of about 60 min with analysis of 30–60 min summed images. This time frame yields excellent data with good image quality in a very short time frame which opens up the opportunity with the shorter-lived \[^{60}\text{Cu}\] to perform multiple imaging sessions. A number of radioactive copper isotopes with longer half lives are available, e.g. \[^{64}\text{Cu}\] (\(t_{1/2} = 12.74\) h)\[29\], enabling wide geographic distribution.

In human studies of lung\[30\] and cervical cancers\[31\], encouraging evidence has emerged that \[^{60}\text{Cu}]\text{ATSM}\ can act as a prognostic indicator for response to therapy. In a prospective study of 14 humans with non-small cell lung cancer, a semi-quantitative analysis of the \[^{60}\text{Cu}]\text{ATSM}\ muscle-to-tumour ratio was able to discriminate those likely to respond to therapy from non-responders\[30\]. A similar study in 14 women with cervical cancer demonstrated a similar predictive value in the tumour response to therapy\[31\].

\section*{Conclusions}

To summarize, tumour hypoxia is common and its effects represents a significant challenge to the curability of human tumours leading to treatment resistance and enhanced tumour progression. Tumour hypoxia can be detected by non-invasive and invasive techniques but the
inter-relationship between these techniques needs to be better defined; human validation of imaging finding is sparse at best. Anti-hypoxia therapies exist in the clinic (but do not work very well or we do not know how to use them optimally) and more are on their way. Hypoxia imaging may allow better definition of a population that would benefit from novel anti-hypoxia directed therapies.

References

[1] Gray LH, Conger AD, Ebert M. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol 1953; 26: 638–48.
[2] Vaupel P. The role of hypoxia-induced factors in tumor progression. Oncologist 2004; 9 (Suppl 5): 10–17.
[3] Brown JM. The hypoxic cell: a target for selective cancer therapy—eighteenth Bruce F. Cain Memorial Award Lecture. Cancer Res 1999; 59: 5863–70.
[4] Vaupel P, Harrison L. Tumor hypoxia: causative factors, compensatory mechanisms, and cellular response. Oncologist 2004; 9 (Suppl 5): 4–9.
[5] Hall EJ, Giaccia AJ. Oxygen effect and reoxygenation. In: Radiobiology for the Radiologist, Hall EJ, Giaccia AJ, eds. Philadelphia: Lippincott Williams & Wilkins, 2006: 85–105.
[6] Ciocca DR, Calderwood SK. Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones 2005; 10: 86–103.
[7] Kallinowski F, Zander R, Hoeckel M, Vaupel P. Tumor tissue oxygenation as evaluated by computerized-pO2-histography. Int J Radiat Oncol Biol Phys 1990; 19: 953–61.
[8] Vaupel P, Schlenker K, Knoop C, Hockel M. Oxygenation of human tumors: evaluation of tissue oxygen distribution in breast cancers by computerized O2 tension measurements. Cancer Res 1991; 51: 3316–22.
[9] Brizel DM, Rosner GL, Harrelson J, Prosnitz LR, Dewhirst MW. Pretreatment oxygenation profiles of human soft tissue sarcomas. Int J Radiat Oncol Biol Phys 1994; 30: 635–42.
[10] Hockel M, Schlenker K, Aral B, Mitze M, Schaffer U, Vaupel P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 1996; 56: 4509–15.
[11] Nordmark M, Bentzen SM, Rudat V et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multicenter study. Radiother Oncol 2005; 77: 18–24.
[12] Hockel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 2001; 93: 266–76.
[13] Bussink J, Kaanders JH, van der Kogel AJ. Tumor hypoxia at the micro-regional level: clinical relevance and predictive value of exogenous and endogenous hypoxic cell markers. Radiother Oncol 2003; 67: 3–15.
[14] Rajendran JG, Krohn KA. Imaging hypoxia and angiogenesis in tumors. Radiol Clin North Am 2005; 43: 169–87.
[15] Caldwell JH, Reavenagh JR, Martin GV, Johnson PM, Rasey JS, Krohn KA. Comparison of fluorine-18-fluorodeoxyglucose and tritiated fluoromisonidazole uptake during low-flow ischemia. J Nucl Med 1995; 36: 1633–8.
[16] Koh WJ, Bergman KS, Rasey JS et al. Evaluation of oxygenation status during fractionated radiotherapy in human nonsmall cell lung cancers using [(F-18)fluoromisonidazole positron emission tomography. Int J Radiat Oncol Biol Phys 1995; 33: 391–8.
[17] Rajendran JG, Wilson DC, Conrad EU et al. Hypoxia and glucose metabolism in malignant tumors: evaluation by [(18)F]fluoromisonidazole and [(18)F]fluorodeoxyglucose positron emission tomography imaging. Clin Cancer Res 2004; 10: 2245–52.
[18] Ng P, Rajendran JG, Schwartz DL, Patterson LM, Scharnhorst J, Krohn KA. Can [(F-18)fluoromisonidazole PET imaging predict treatment response in head and neck cancer? J Nucl Med 2003; 44: 128P.
[19] Rajendran JG, Mankoff DA, O’Sullivan F et al. Hypoxia and glucose metabolism in malignant tumors: evaluation by [(18)F]fluoromisonidazole and [(18)F]fluorodeoxyglucose positron emission tomography imaging. Clin Cancer Res 2004; 10: 2245–52.
[20] Hicks RJ, Rischin D, Fisher R, Binns D, Scott AM, Peters LJ. Utility of FMISO PET in advanced head and neck cancer treated with chemoradiation incorporating a hypoxia-targeting chemotherapy agent. Eur J Nucl Med Mol Imaging 2005; 32: 1384–91.
[21] Fujibayashi Y, Taniuchi H, Yonekura Y, Ohtani H, Konishi J, Yokoyama A. Copper-62-ATSM: A new hypoxia imaging agent with high membrane permeability and low redox potential. J Nucl Med 1997; 38: 1155–60.
[22] Dearling JLD, Lewis JS, Mullen GED, Rae MT, Zweit J, Blower PJ. Design of hypoxia-targeting radiopharmaceuticals: Selective uptake of copper-64 complexes in hypoxic cells in vitro. Eur J Nucl Med 1998; 25: 788–92.
[23] Dearling JLD, Lewis JS, Welsh MJ, McCarthy DW, Blower PJ. Redox-active complexes for imaging hypoxic tissues: Structure-activity relationships in copper(II)bis(thiosemicarbazone) complexes. Chem Commun 1998; 22: 2531–3.
[24] Lewis JS, McCarthy DW, McCarthy TJ, Fujibayashi Y, Welsh MJ. The evaluation of 64Cu-diacetyl-bis(N4-methylthiosemicarbazone)(64Cu-ATSM) in vivo and in vitro in a hypoxic tumor model. J Nucl Med 1999; 40: 177–83.
[25] Lewis JS, Sharp TL, Laforest R, Fujibayashi Y, Welsh MJ. Tumor uptake of copper-diacetyl-bis(N4-methylthiosemicarbazone): effect of changes in tissue oxygenation. J Nucl Med 2001; 42: 655–61.
[26] Dearling JL, Lewis JS, Mullen GE, Welsh MJ, Blower PJ. Copper bis(thiosemicarbazone) complexes as hypoxia imaging agents: structure-activity relationships. J Biol Inorg Chem 2002; 7: 249–59.
[27] Lewis JS, Herrero P, Sharp T et al. Delineation of hypoxia in canine myocardium using PET and copper(II)-diacetetyl-bis(N4-methylthiosemicarbazone). J Nucl Med 2002; 43: 1557–69.
[28] Maurer RI, Blower PJ, Dilworth JR, Reynolds CA, Zheng Y, Mullen GED. Studies on the mechanism of hypoxic selectivity in copper bis(thiosemicarbazone) radiopharmaceuticals. J Med Chem 2002; 45: 1420–31.
[29] Blower PJ, Lewis JS, Zweit J. Copper radionuclides and radiopharmaceuticals in nuclear medicine. Nucl Med Biol 1996; 23: 957–80.

[30] Dehdashti F, Mintun MA, Lewis JS et al. In vivo assessment of tumor hypoxia in lung cancer with $^{60}$Cu-ATSM. Eur J Nucl Med Mol Imaging 2003; 30: 844–50.

[31] Dehdashti F, Grigsby PW, Mintun MA, Lewis JS, Siegel BA, Welch MJ. Assessing tumor hypoxia in cervical cancer by positron emission tomography with $^{60}$Cu-ATSM: relationship to therapeutic response—a preliminary report. Int J Radiat Oncol Biol Phys 2003; 55: 1233–8.

[32] Koh WJ, Rasey JS, Evans ML et al. Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole. Int J Radiat Oncol Biol Phys 1992; 22: 199–212.

[33] Rasey JS, Koh WJ, Evans ML et al. Quantifying regional hypoxia in human tumors with positron emission tomography of $[^{18}F]$fluoromisonidazole: a pretherapy study of 37 patients. Int J Radiat Oncol Biol Phys 1996; 36: 417–28.

[34] Eschmann SM, Paulsen F, Reimold M et al. Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. J Nucl Med 2005; 46: 253–60.

[35] Pietr M, Machulla HJ, Picchio M et al. Hypoxia-specific tumor imaging with 18F-fluoroazomycin arabinoside. J Nucl Med 2005; 46: 106–13.

[36] Evans SM, Kachur AV, Shiue CY et al. Noninvasive detection of tumor hypoxia using the 2-nitroimidazole $[^{18}F]$EF1. J Nucl Med 2000; 41: 327–36.

[37] Howe FA, Robinson SP, McIntyre DJ, Stubbs M, Griffiths JR. Issues in flow and oxygenation dependent contrast (FLOOD) imaging of tumours. NMR Biomed 2001; 14: 497–506.